ArticleMolecular pain2017
Potential protein biomarkers for burning mouth syndrome discovered by quantitative proteomics.
Article in Molecular pain, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Morpho-Histo-Cytological Evaluation of Oral Tissues in Burning Mouth Syndrome: A Systematic Review.Journal of oral rehabilitation · 2025Pooled it
- Neuropathic and Psychogenic Components of Burning Mouth Syndrome: A Systematic Review.Biomolecules · 2021Pooled it
- Trial
- Review
- Changes in salivary biomarkers of burning mouth syndrome patients after clonazepam treatment.Journal of oral & facial pain and headache · 2024Article
- Comprehensive analysis of the oral microbiota and metabolome change in patients of burning mouth syndrome with psychiatric symptoms.Journal of oral microbiology · 2024Article
- Applications of Tandem Mass Spectrometry (MS/MS) in Protein Analysis for Biomedical Research.Molecules (Basel, Switzerland) · 2022Review
- Salivary proteome of aphthous stomatitis reveals the participation of vitamin metabolism, nutrients, and bacteria.Scientific reports · 2021Article
- Proteomics-Based Identification of Salivary Changes in Patients with Burning Mouth Syndrome.Biology · 2021Article
- Metabolomics of Oral/Head and Neck Cancer.Advances in experimental medicine and biology · 2021Article
- Unravelling the Potential of Salivary Volatile Metabolites in Oral Diseases. A Review.Molecules (Basel, Switzerland) · 2020Review
- Saliva proteomic patterns in patients with molar incisor hypomineralization.Scientific reports · 2020Article
- Protein Signature in Saliva of Temporomandibular Disorders Myalgia.International journal of molecular sciences · 2020Article
- Proteomic profiling of whole-saliva reveals correlation between Burning Mouth Syndrome and the neurotrophin signaling pathway.Scientific reports · 2019Article
- Protein-Based Salivary Profiles as Novel Biomarkers for Oral Diseases.Disease markers · 2018Review
- Biomarkers in orofacial pain conditions: A narrative review.Journal of oral biology and craniofacial researchReview
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Burning mouth syndrome (BMS) is a chronic pain disorder characterized by severe burning sensation in normal looking oral mucosa. Diagnosis of BMS remains to be a challenge to oral healthcare professionals because the method for definite diagnosis is still uncertain. In this study, a quantitative saliva proteomic analysis was performed in order to identify target proteins in BMS patients' saliva that may be used as biomarkers for simple, non-invasive detection of the disease. By using isobaric tags for relative and absolute quantitation labeling and liquid chromatography-tandem mass spectrometry to quantify 1130 saliva proteins between BMS patients and healthy control subjects, we found that 50 proteins were significantly changed in the BMS patients when compared to the healthy control subjects ( p ≤ 0.05, 39 up-regulated and 11 down-regulated). Four candidates, alpha-enolase, interleukin-18 (IL-18), kallikrein-13 (KLK13), and cathepsin G, were selected for further validation. Based on enzyme-linked immunosorbent assay measurements, three potential biomarkers, alpha-enolase, IL-18, and KLK13, were successfully validated. The fold changes for alpha-enolase, IL-18, and KLK13 were determined as 3.6, 2.9, and 2.2 (burning mouth syndrome vs. control), and corresponding receiver operating characteristic values were determined as 0.78, 0.83, and 0.68, respectively. Our findings indicate that testing of the identified protein biomarkers in saliva might be a valuable clinical tool for BMS detection. Further validation studies of the identified biomarkers or additional candidate biomarkers are needed to achieve a multi-marker prediction model for improved detection of BMS with high sensitivity and specificity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.